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Abstract 
Objective: This opinion piece encourages mental health researchers and clinicians to engage with 
mental health issues among tuberculosis patients in the Asia-Pacific region in a culturally appropriate 
and ethical manner. The diversity of cultural contexts and the high burden of tuberculosis 
throughout the Asia-Pacific presents significant challenges. Research into tuberculosis and mental 
illness in this region is an opportunity to develop more nuanced models of mental illness and 
treatment, while simultaneously contributing meaningfully to regional tuberculosis care and 
prevention.  
Conclusions: We overview key issues in tuberculosis and mental illness comorbidity, highlight ethical 
concerns, and advocate for a regional approach to tuberculosis and mental health that is consistent 
with the transnational challenges presented by this airborne infectious disease. Integrating 
tuberculosis and mental health services will go a long way to addressing the needs of vulnerable 
populations and stopping the transmission of one of the world’s biggest infectious killers. 
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Despite being preventable, treatable, and curable, tuberculosis (TB) remains a leading cause of 
mortality worldwide, with 95% of deaths occurring in low-income countries.1 TB is an airborne 
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infection, which makes disease control a fundamentally transnational challenge. Global TB 
elimination will require intense collaboration between low-, middle- and upper-income countries. 
 
Australia is positioned to serve a leadership role in the Asia-Pacific region, given its strong programs 
of TB research as well as its strategic geographic location. Currently, the region hosts 58% of the 
global TB burden, including 54% of all estimated multidrug resistant (MDR) cases.2 Nine of Australia's 
closest neighbours have a high TB burden.3 The majority of TB cases in Australia occur among 
immigrants and other recent arrivals from high incidence countries, who probably acquired the 
infection before arrival.4 The most frequently reported countries of birth for Australian TB cases in 
2012 and 2013 were India, followed by Vietnam, the Philippines, China, Nepal, Indonesia, Papua 
New Guinea, Afghanistan, Myanmar and Cambodia.5 Given the diverse origins of TB patients in 
Australia, research in collaboration with these patient cohorts can provide preliminary insights into 
TB care and prevention in other countries. Expanding TB research on prevention and care in the 
Asia-Pacific region will not only benefit neighbouring high burden countries, but may also be a cost-
effective method of lowering TB incidence at home.6 This opportunity to develop a cross-national, 
collaborative approach to TB care and prevention may prove useful to other regions. 
 
Comorbid mental illness is a significant unrecognised challenge to TB care and prevention in 
Australia and its bordering high burden countries. People living with TB and mental illness are at 
greater risk of poor health-seeking behaviour, and medication adherence with consequent adverse 
treatment outcomes including morbidity, mortality, drug-resistance, and ongoing disease 
transmission.7 The prevalence of mental illness among TB patients may be as high as 70%.8 
Psychiatric comorbidity in TB patients has been found to relate to higher levels of physical and social 
disability.9 High rates of depression and anxiety among TB patients relate to physiological 
disturbances, social stigma, and inadequate social support.10 Additionally, several anti-tuberculosis 
medications, such as cycloserine, may precipitate more severe forms of mental illness—including 
major depression, anxiety or psychosis.8,11 TB and mental illness share common risk factors including 
poverty, substance abuse and homelessness.8 Both syndromes have a disproportionate impact upon 
socially marginalised populations. Improved understanding of, and responses to, comorbid mental 
illness in patients with TB will serve to strengthen efforts to reduce global disease transmission. 
 
The negative interplay between mental illness and TB is substantial. Recognition of the association 
provides opportunities for action. Individual psychotherapy for TB patients in India can improve 
treatment adherence and completion,12 TB support groups in rural Ethiopia have increased 
community awareness, case detection, clinic attendance and treatment adherence,13 and group 
psychotherapy for MDR-TB patients in Peru, with adjunctive psychotropic medications when 
indicated, improved treatment adherence, completion, and social rehabilitation after treatment.14,15 
The very origins of group psychotherapy—and indeed, cognitive behavioural therapy—are credited 
to a Boston Internist, Dr. Joseph Pratt, who in 1905 developed a “class method” for the home-based 
treatment of TB involving home visits and regular support group meetings, which he hailed to be a 
critical element of the program’s success.16,17 Evidently, addressing the mental health needs of TB 
patients can improve both patient wellbeing and treatment outcomes. By tackling mental and 
physical aspects of TB simultaneously, ongoing transmission of the infection can be reduced, offering 
benefits for the global community.  
 
Attending to the issue of co-morbid mental illness among people with TB in cross-national settings 
such as the Asia-Pacific region presents significant programmatic challenges. The treatment settings 
are diverse, infrastructure is frequently lacking, and local idioms and manifestations of mental 
distress are often poorly understood. Most psychiatric screening tools and evidence-based 
treatment interventions in mental health were developed in high-income countries, and it can be 
difficult to “translate” them across diverse sociocultural, economic, political and linguistic settings, 
where there are few, if any, mental health specialists. Furthermore, as both mental illness and TB 
are already highly stigmatised, the issue of co-morbidity should be approached delicately. Any 
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association between TB and mental illness needs to be presented, framed and disseminated in ways 
that do not exacerbate existing social stigmas. Addressing mental illness and TB is a moral 
imperative, but one that should take into consideration significant ethical dimensions such as the 
translation of mental health initiatives across cultures. 
 
With a culturally-sensitive approach, Australian experience in TB and mental health can provide 
effective support and guidance to resource-limited countries within the region, and serve as a model 
for transnational collaboration for TB control. Existing diagnostic tools for mental illness should not 
be taken to be universally-applicable without proper testing among diverse populations,18 and any 
psychotherapeutic tool should be considered as one of many different options. Locally-appropriate 
approaches should be prioritised. Mental health diagnostics, treatments, and stigma-reduction 
interventions need to be carefully designed and tested before being implemented alongside TB 
treatment programs.  
 
Developing strategies to bolster infectious disease control by addressing mental health issues among 
TB patients throughout the Asia-Pacific will allow Australia to contribute to, and benefit from, 
regional TB prevention and care. An integrated approach to TB is fundamental to achieving the best 
individual and public health outcomes. Mental health research among TB patients provides an 
opportunity to develop more robust and dynamic models of care for people with mental illness 
while simultaneously addressing the needs of vulnerable populations.  
 
TB thrives under conditions of poverty and neglecting mental illness in these populations is both 
unethical and unwise, given the potential negative synergy and impact on treatment outcomes. 
Concurrently, using global TB infrastructure to spread and promote models of psychiatric treatment 
that are untested in diverse cultural contexts is also unethical. Globalising culture-specific models of 
therapy risks steamrolling local variations in mental illness and possibly overriding local buffers 
against psychopathology.19 Since local factors are likely important in understanding the interplay 
between TB and mental illness, it is clinically and ethically imperative that evidence-based tools and 
interventions are locally adapted to balance fidelity and fit in new settings.20,21 It is incumbent upon 
those offering care for patients with TB to ensure that mental health interventions do not cause 
more harm, burden TB patients with the double stigma of mental and infectious disease, or turn 
immediately to pharmaceutical solutions to address problems that may be interpersonal, economic, 
or social in aetiology.  
 
Global health and international development programs have a history of treating social issues as 
biomedical problems, leading to little more than the pharmaceuticalisation of poverty.22 There is 
reason to be cautious about approaches that too narrowly focus on pharmacotherapy,23 use TB 
patients as an excuse to expand pharmaceutical markets,24 or apply diagnostic standards without 
attending to cultural and contextual factors.25 With a view to testing interventions that are 
sustainable within resource-limited healthcare systems, psychotherapeutic treatment may offer one 
testable treatment model that can be cost-effective,26,27 achieve equivalent efficacious outcomes to 
pharmaceutically treated mental illness,28 and provide benefits that are maintained post-
treatment.29,30 Even in low-resource settings, non-specialists can be trained to deliver basic 
psychotherapeutic interventions with expert supervision.31 That said, adjunctive pharmaceutical 
interventions may be indicated for individuals not well suited for psychotherapy, or whose 
symptoms can be attributed to psychiatric side effects associated with anti-TB medications.8,32 With 
an ethical motivation to foster effective, locally-appropriate mental health services, programs need 
to be developed that are self-reliant, sustainable, and not conditional on foreign aid, infrastructure 
and imports. 
 
Australia is in a unique position to provide leadership on TB and mental health research in the Asia-
Pacific. Such research has an important role in uncovering the complex nexus between psychosocial, 
cultural and physical manifestations of TB within and across diverse communities. Developing 
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methods to address mental health issues associated with TB will lead to innovative approaches to TB 
care and prevention. Innovations might improve disease control but may also challenge or disrupt 
established control methods. Addressing mental health and TB should not begin with answers, but 
with questions, and the process of enquiry will be ongoing. Research should be aimed at 
understanding the experience of people living with TB, their health-seeking behaviour, and their 
strategies for coping with diagnosis, treatment initiation and medication adherence within the 
context of their living and social situation. Randomised controlled trials of potential mental health 
interventions would be best accompanied by operational research into service delivery integration 
as well as ethnographic research into the wider, unintended effects of implementing mental health 
services in diverse cultural settings. The research paradigms should focus on building reciprocity and 
establishing long-lasting cross-national partnerships, with the understanding that the lessons learnt 
are bi-directional. 
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